Milgamma

Method of action: Vitamins

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Milgamma

Property	Description
Active Ingredients	Benfotiamine (Vitamin B₁ derivative), Pyridoxine HCl (Vitamin B₆)
Form	Film-coated tablets, Solution for injection (Ampoules)
Pharmacological Class	Neurotropic B Vitamin Complex, Combination Product
Common Use	Support of neurological function and nerve tissue health
Origin	Synthetic Vitamin Derivative (Benfotiamine)

Milgamma is defined as a fixed-dose combination product belonging to the neurotropic B vitamin complex pharmacological class, clinically recognized for its targeted support of nerve health. This formulation is specifically designed to provide essential B vitamins at high concentrations to support the nervous system. It is available as film-coated tablets for oral administration and a sterile solution for injection contained in ampoules, designated for intramuscular use. This availability in distinct dosage forms ensures flexibility, a key differentiating feature that allows for intensive initial supply or consistent maintenance support based on the required therapeutic approach.

Composition: Benfotiamine, Pyridoxine, and Enhanced Bioavailability

The active composition of Milgamma centers on the pairing of Benfotiamine and Pyridoxine Hydrochloride (Vitamin B₆). Benfotiamine is a synthetic, lipid-soluble derivative of Thiamine (Vitamin B₁), which distinguishes it fundamentally from standard, water-soluble thiamine forms. This specialized chemical structure allows Benfotiamine to exhibit superior absorption and subsequent enhanced bioavailability compared to traditional thiamine salts, enabling it to penetrate and reach target nerve tissues more effectively.

General Purpose and Benefit to the Nervous System

The general purpose of the Milgamma combination is to provide direct neurotrophic (nerve-feeding) support and essential metabolic factors to the nervous system. The active B vitamins act as essential metabolic cofactors for enzymes critical to nerve cell energy production and the synthesis of important neurological components. The formulation's primary benefit is to support the regenerative capacity of nerve fibers and help protect nerve tissue from metabolic stress, contributing to the maintenance of normal nerve signaling and function.

Regulatory References

Vitamin B6 (Pyridoxine) StatPearls Review

What side effects are possible with Milgamma?

Possible Side Effects and Safety Information

The official safety profile for Milgamma tablets, which contain Benfotiamine (a Vitamin B1 derivative) and Pyridoxine ( B6), classifies most documented adverse reactions as Very Rare (occurring in fewer than 1 in 10,000 users). These reactions are typically categorized by the body system affected, according to regulatory standards.

Adverse Reaction Scope

Classification Category	Documented Effects	System-Organ Class Involved
Very Rare	Hypersensitivity reactions (hives, skin rashes, asthma)	Immune System Disorders
Very Rare	Gastrointestinal disorders (e.g., flatulence, nausea, abdominal pain, diarrhoea, constipation)	Gastrointestinal Disorders
Very Rare	Acneiform and bullous (blistering) rashes	Skin and Subcutaneous Tissue Disorders

Safety-Related Restrictions and Limitations

Regulatory documents include specific constraints on use. The product is formally contraindicated in cases of suspected hypersensitivity to the active ingredients or excipients, and in patients with ileus.

Due to certain excipients, such as castor oil, patients may experience nausea, vomiting, or a laxative effect. Furthermore, the presence of sugars like lactose and glucose means the medicine is contraindicated for patients with rare hereditary sugar intolerances (e.g., lactose intolerance, glucose-galactose malabsorption).

Population-Specific Safety Considerations

Official safety information addresses use during physiological states. For pregnancy, Vitamin B1 dosage may only exceed the standard recommended daily intake if a deficiency is officially diagnosed, as safety at higher concentrations is not established. Pyridoxine (Vitamin B6) is documented to be excreted into breast milk.

Overdose and Emergency Response

Overdose and When to Seek Help

The documented clinical profile for toxicity associated with this product is primarily related to the long-term, high-dose intake of its Pyridoxine (Vitamin B6) component, which is established in regulatory documents as capable of causing neurological injury.

Overdose Profile: Signs and Action	Regulatory Statement
Documented Manifestations	Sensory Neuropathy, characterized by tingling, burning, or numbness (paresthesia), typically beginning in the hands and feet. This manifestation is directly associated with chronic, high-dose exposure to Pyridoxine.
Severe Outcome Risk	Continued exposure following the onset of symptoms can lead to the progression of nerve damage and the potential for severe, permanent peripheral neuropathies.
Immediate Action Required	Official labeling mandates that the medication must be stopped immediately if symptoms such as tingling, burning, or numbness occur. You must seek medical attention from a healthcare practitioner as soon as possible.

Official Management and Treatment

The standard regulatory procedure for managing this toxicity involves symptomatic and supportive treatment, as no specific chemical antidote is known or documented for Pyridoxine overdose. Management centers on the immediate and permanent cessation of the product. The withdrawal from high-dose Pyridoxine may need to be supervised by a clinician to manage any potential transient dependency symptoms. Continuous medical monitoring may be required to assess the severity and progression of the neurological symptoms.

Therapeutic Uses of Milgamma

What Milgamma Treats: Main Uses and Benefits

Milgamma is commonly applied across domains where additional symptomatic support is needed in conditions where peripheral nerves are compromised due to metabolic conditions, notably diabetic polyneuropathy and alcoholic polyneuropathy. This application is relevant in therapeutic areas involving supportive symptom management. It helps address symptom clusters that may become intense or disruptive, such as the frequent and distressing patterns of tingling, burning, and numbness (paresthesia) typically felt in the extremities. This supportive use contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

The formulation is also applied in clinical settings that involve acute or unstable symptom patterns where pain arises from nerve root irritation, including lumbosacral radiculopathy and various forms of neuritis, and is relevant for managing the symptoms linked to clinical Vitamin B1 deficiency. This application supports patients during difficult episodes by contributing to easing the overall symptom load.

Quick Fact: Relief for Neuropathic Distress
Milgamma is relevant for managing symptoms that interfere with daily comfort, particularly the specific altered sensations and pain components seen in chronic nerve conditions.

Regulatory References

Thiamine (Vitamin B1) Overview from MedlinePlus

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Milgamma — Official Regulatory Information

The official regulatory profile for Milgamma strictly defines which populations are eligible to use the medicine.

Eligibility Scope

Category	Official Regulatory Statement
Populations for Whom Use is Allowed	Adults are the approved population for whom the medicine is indicated.
Populations for Whom Use is Contraindicated	Individuals with known or suspected hypersensitivity to Benfotiamine, Pyridoxine, or any excipient.
Age-Related Eligibility Rules	Use is approved for adults. Safety and efficacy have not been established for children under 18 years of age.
Condition-Specific Eligibility Rules	Contraindicated in patients diagnosed with ileus (intestinal obstruction).
Pregnancy and Lactation Eligibility Status	High-dose Vitamin B6 (e.g., 100 mg ampoules) should be avoided. High-dose B1 is permitted only for a diagnosed deficiency.
Eligibility-Related Restrictions	Exclusion for patients with hereditary disorders such as fructose intolerance, lactose intolerance, or glucose-galactose malabsorption due to excipient content.

Eligibility Classifications (High-Level)

Classification Type	Regulatory Wording and Context
Eligibility Severity Classification	Contraindicated (Hypersensitivity, Ileus), Not Established (Pediatrics), Avoid/Conditional Use (Pregnancy/Lactation).
Regulatory Basis	Regulatory data derived from SmPC (Summary of Product Characteristics).
Eligibility-Context Constraints	Excipient-related constraints and specific Comorbidity constraints (e.g., ileus, psoriasis—the latter requires caution).

Resulting Eligibility Structure

Official Eligibility Statements:

The medicine is officially indicated for use only in the adult population.
Use is contraindicated in patients with a suspected hypersensitivity to the active ingredients or to any excipient.
Safety and efficacy have not been established for children under 18 years of age.

Connection to the overall eligibility profile (2–4 sentences): The regulatory documents define Milgamma's eligibility profile by permitting use in adults while explicitly contraindicating use based on hypersensitivity, the presence of ileus, or excipient intolerances. Use in the pediatric population is not established, and specific restrictions mandate avoidance of high doses during pregnancy and lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Milgamma, a fixed-dose combination of Benfotiamine ( Vitamin B1 derivative) and Pyridoxine ( Vitamin B6), establishes several clinically significant interaction patterns.

Pharmacological Antagonism and Restrictions

Interacting Agent	Interaction Outcome and Restriction
Levodopa	Pyridoxine at doses of mathbf5 mg or greater reduces the therapeutic effect of Levodopa through antagonism. This combination is restricted unless a decarboxylase inhibitor (e.g., Carbidopa) is co-administered.
B1 Antagonists	Thiamine components are functionally neutralized by antagonists such as mathbf5 -fluorouracil and Thiosemicarbazone.

Exposure-Modifying Substances

Several medications are documented to alter the body's exposure to the B vitamins. Agents like Isoniazid (INH), D-penicillamine, and Oral Contraceptives may significantly increase the requirement for the Pyridoxine component due to changes in its metabolism or bioavailability. Conversely, Pyridoxine is documented to decrease the plasma concentrations of anticonvulsant agents such as Phenobarbital and Phenytoin.

Other Constraints

The absorption of both Thiamine and Pyridoxine is reduced by the concurrent consumption of Alcohol. For the solution for injection, the Thiamine component is completely degraded by solutions containing sulfite, necessitating strict separation during administration.

Mechanism of Action

Metabolic Neuroprotection and Anti-Stress Action

This mechanism covers the action of Benfotiamine (the B₁ derivative), which increases the activity of the enzyme Transketolase within nerve cells. By functioning as an essential cofactor, this action effectively diverts harmful glycolytic intermediates away from pathways that generate toxic Advanced Glycation End-products (AGEs). This diversion results in the reduction of AGEs and the modulation of associated signaling pathways in peripheral nerve fibers.

Structural Support and Neural Signaling Modulation

This mechanism is driven by Pyridoxine (Vitamin B₆), which acts as the cofactor Pyridoxal 5-Phosphate (PLP) for a large number of synthetic enzymes. PLP is necessary for the biosynthesis of both structural lipids (like sphingolipids) that contribute to the myelin sheath and key inhibitory neurotransmitters (like GABA). The mechanism thus enables the biosynthesis of components critical to the structure of the nerve fiber and facilitates the modulation of signal transmission within the nervous system.

Dosage and Administration Information

Milgamma is administered using a strictly defined, two-phase procedural protocol based on its available forms: oral film-coated tablets and a sterile solution for intramuscular (IM) injection. This dual route determines the overall usage pattern.

Initial Treatment Phase (Intramuscular)

The protocol begins with the initial treatment phase, which uses the intramuscular route. The standard regimen for this acute period involves the administration of one ampoule daily as a deep intramuscular injection to establish a rapid supply of the active substances. However, this parenteral route is constrained by duration. The IM course must not exceed 14 days before the patient transitions to the oral preparation.

Maintenance Phase (Oral)

The maintenance phase then involves the use of the film-coated tablets. The standard oral dosing typically ranges from one to three tablets daily, which should be swallowed whole with a sufficient amount of liquid. If a dose is missed, taking a double dose for compensation is not recommended. Use in the pediatric population is generally not established. Furthermore, the IM form is restricted during pregnancy and lactation due to the high Pyridoxine content.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Milgamma

This section outlines the research that has been studied for the active ingredients in Milgamma (Benfotiamine, a derivative of Vitamin B1, and Vitamin B6) as reported in authoritative sources and peer-reviewed scientific literature. This summary describes the types of clinical studies performed, based on the findings documented in the authorized research, without providing clinical advice or treatment recommendations.

Evidence for Use in Diabetic Polyneuropathy

Research was studied for use of the active ingredients in adults with diabetic polyneuropathy (DPN), a condition where outcomes related to physical discomfort arise. Study designs included randomized controlled trials (RCTs), often comparing the active ingredients to an inactive substance (placebo).

Researchers focused on two main kinds of outcomes: patient-reported experiences (symptom scales) and objective measurements (nerve conduction speed). Studies focused on symptoms were often short-term, lasting a few weeks to three months. Findings were mixed, and data show patterns related to limited consistency between changes in patient-reported experiences and objective measurements.

Some trials reported measurements reflecting patterns of change in patient-reported discomfort, particularly over short periods. However, other studies focusing on objective measurements of nerve function over longer periods did not consistently describe clear patterns. This evidence contributes to the broader evidence landscape; however, research does not determine whether an individual will respond similarly.

Evidence for Symptomatic Support in Acute Nerve Root Irritation

Research examined whether the active ingredients, used as an add-on therapy, influence outcomes related to physical discomfort associated with conditions involving periods of heightened symptoms like lumbosacral radiculopathy.

The research typically examined how symptoms evolved when adding the active ingredients to commonly used pain relief medications (like NSAIDs), comparing that combination to the standard treatment alone. Data show patterns related to changes in outcomes related to physical discomfort and study duration when the active ingredients was associated with the standard analgesic treatment.

Comparative evidence is lacking for using the active ingredients as a single agent (monotherapy) for acute pain. The results apply primarily to the combination scenario.

Evidence Gaps and Areas for Future Research

The overall evidence contributes to the broader evidence landscape; however, research also highlights several limitations and areas where certainty remains low. Key limitations include that sample sizes were modest in some influential trials for polyneuropathy. The evidence quality varies across studies, and findings were often mixed, particularly regarding whether observed patterns in patient-reported discomfort align with patterns of change in objective nerve function tests.

Furthermore, comparative evidence is lacking regarding how the active ingredients was evaluated in studies against other forms of B vitamins or other long-term nerve support treatments. Subgroup findings are uncertain, as the research applies only to the populations studied. The research provides context but not individual predictions.

Key Studies & References

Public Summary SwissPAR – milgamma® (active substance: benfotiamine)

Frequently Asked Questions (FAQ)

Common questions about Milgamma (FAQ)

Q: What is the specific Vitamin B6 (Pyridoxine) content per tablet?

According to the official product information, each film-coated tablet of Milgamma contains 100 mg of Benfotiamine ( Vitamin B1 derivative) and 100 mg of Pyridoxine hydrochloride ( Vitamin B6). The specific content of the active ingredients is detailed in the regulatory documents for the product’s composition.

Q: How should I store the Milgamma solution for injection (ampoules)?

Regulatory documents state that the Milgamma solution for injection must be kept in its original container. This storage requirement is intended to protect the product from light, which helps maintain the stability and viability of the active ingredients.

Q: What is the average time it takes for Milgamma to start relieving symptoms?

Official product information does not specify an average time for the relief of symptoms. Clinical studies reviewed for the active ingredients often focused on short-term periods, such as a few weeks or months. The findings regarding changes in patient-reported experiences have been mixed, and a specific timeline for the onset of action is not established in the product information.

How should Milgamma be stored and disposed of?

Storage Conditions

Milgamma film-coated tablets must be stored at a temperature not exceeding 25, C. The medicine must be kept in its original package to ensure protection from environmental factors, specifically light and moisture. Correct storage is essential for maintaining the product's stability and ensuring it remains viable up to its labeled expiry date.

Packaging and Child Safety

The container must be kept tightly closed where applicable to prevent moisture exposure. Consistent with regulatory requirements for all medicinal products, Milgamma must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Milgamma should be disposed of properly to protect the environment. The preferred method is to return the medicine to an authorized collection point, such as a pharmacy take-back program. Disposal by flushing the product down the sink or toilet is prohibited unless the official labeling specifically instructs otherwise. If no take-back program is available, the tablets should be mixed with an undesirable substance (e.g., used coffee grounds), sealed in a bag or container, and discarded in the household trash, after scratching out all personal information on the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.